Research graph
References from A Human Glucoregulatory Model for the Rational Design and Evaluation of Diabetes Therapeutics. Local targets link to admitted publications; unresolved targets remain external evidence.
The Pathophysiology, Presentation and Classification of Type 1 Diabetes
10.1111/dom.16628 · 2025 · External reference
Type 1 Diabetes Mellitus
10.1038/nrdp.2017.16 · 2017 · External reference
Type 1 and Type 2 Diabetes Mellitus: Commonalities, Differences and the Importance of Exercise and Nutrition
10.3390/nu15194279 · 2023 · External reference
Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Provisional Report of a WHO Consultation
10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · 1998 · External reference
Diabetes and Heart Disease
10.2337/diacare.26.10.2947 · 2003 · External reference
Epidemiology of Diabetes and Diabetes-Related Complications
10.2522/ptj.20080020 · 2008 · External reference
Unresolved reference
External reference
Economic Costs of Diabetes in the U.S. in 2022
10.2337/dci23-0085 · 2024 · External reference
Animal Models in Diabetic Research─History, Presence, and Future Perspectives
10.3390/biomedicines11102852 · 2023 · External reference
Rational Design and Efficacy of Glucose-Responsive Insulin Therapeutics and Insulin Delivery Systems by Computation Using Connected Human and Rodent Models
10.1002/adhm.202300587 · 2023 · External reference
Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling
10.1002/adhm.201700601 · 2017 · External reference
ViVo: A Temporal Modeling Framework That Boosts Statistical Power and Minimizes Animal Usage
10.1021/acs.jmedchem.5c03326 · 2026 · External reference
In-Silico Experiments of Zebrafish Behaviour: Modeling Swimming in Three Dimensions
10.1038/srep39877 · 2017 · External reference
A Computational Glucoregulatory Model of Liver and Glucagon for the Evaluation of Therapeutics
10.1021/acsptsci.5c00177 · 2025 · External reference
Insulin Therapy and Exercise
10.1016/s0168-8227(11)70017-1 · 2011 · External reference
Clinical Utility of Insulin and Insulin Analogs
10.4161/isl.24590 · 2013 · External reference
Pursuit of a Perfect Insulin
10.1038/nrd.2015.36 · 2016 · External reference
Intensive Insulin Therapy (Basal-Bolus)
10.1097/mjt.0000000000001152 · 2022 · External reference
Glucose-Responsive Insulin and Glucagon Delivery (Dual-Hormone Artificial Pancreas) in Adults with Type 1 Diabetes: A Randomized Crossover Controlled Trial
10.1503/cmaj.121265 · 2013 · External reference
Metabolic Effects of Glucagon in Humans
10.1016/j.jcte.2018.12.005 · 2019 · External reference
Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?
10.3390/biom11091281 · 2021 · External reference
Hemoglobin A1C
2024 · External reference
Unresolved reference
External reference
Diabetes: Advances in Diagnosis and Treatment
10.1001/jama.2015.9536 · 2015 · External reference
Retained Diabetes Devices─A Literature Review
10.1177/19322968221105895 · 2023 · External reference
Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
10.1007/s00125-022-05744-z · 2023 · External reference
Inpatient Use of Automated Insulin Delivery Systems
10.1177/19322968251412442 · 2026 · External reference
Engineering a Pathway to Glucose-Responsive Therapeutics
10.2337/dbi23-0029 · 2024 · External reference
Glucose-Sensitive Insulin with Attenuation of Hypoglycaemia
10.1038/s41586-024-08042-3 · 2024 · External reference
Shrinking Fabrication of a Glucose-Responsive Glucagon Microneedle Patch
10.1002/advs.202203274 · 2022 · External reference
Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation
10.1002/adma.201902004 · 2020 · External reference
Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design
10.1021/acsmaterialsau.4c00138 · 2025 · External reference
Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties
10.1002/cpt.1215 · 2019 · External reference
A Model-Informed Drug Discovery and Development Strategy for the Novel Glucose-Responsive Insulin MK-2640 Enabled Rapid Decision Making
10.1002/cpt.1729 · 2020 · External reference
In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins
10.1021/acsptsci.3c00095 · 2023 · External reference
Computer-Aided Drug Discovery and Development (CADDD): In Silico-Chemico-Biological Approach
10.1016/j.cbi.2006.12.006 · 2008 · External reference
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare
10.3390/pharmaceutics16030332 · 2024 · External reference
The UVA/PADOVA Type 1 Diabetes Simulator
10.1177/1932296813514502 · 2014 · External reference
The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
10.1177/1932296818757747 · 2018 · External reference
Meal Simulation Model of the Glucose-Insulin System
10.1109/tbme.2007.893506 · 2007 · External reference
Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes
10.1088/0967-3334/25/4/010 · 2004 · External reference
Unresolved reference
External reference
A Pharmacokinetic Model of a Tissue Implantable Insulin Sensor
10.1002/adhm.201400264 · 2015 · External reference
Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin
10.2337/db19-0879 · 2020 · External reference
Development of Appropriate Equations for Physiologically Based Pharmacokinetic Modeling of Permeability-Limited and Flow-Limited Transport
10.1007/s10928-011-9200-x · 2011 · External reference
Unresolved reference
External reference
Pharmacokinetic and Glucodynamic Comparisons of Recombinant and Animal-Source Glucagon after IV, IM, and SC Injection in Healthy Volunteers
10.1021/js99007p · 1999 · External reference
Low Doses of Dasiglucagon Consistently Increase Plasma Glucose Levels from Hypoglycaemia and Euglycaemia in People with Type 1 Diabetes Mellitus
10.1111/dom.13562 · 2019 · External reference
Pharmacokinetics, Pharmacodynamics and Glucose Counterregulation Following Subcutaneous Injection of the Monomeric Insulin Analogue [Lys(B28),Pro(B29)] in IDDM
10.1007/bf00417697 · 1994 · External reference
Improved Postprandial Glycaemic Controls with Insulin Aspart in Type 2 Diabetic Patients Treated with Insulin
10.1007/s005920070034 · 2000 · External reference
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
10.2337/dc17-1402 · 2018 · External reference
Diabetes: Mechanism, Pathophysiology and Management-A Review
2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Nonlinear Regression Modelling: A Primer with Applications and Caveats
10.1007/s11538-024-01274-4 · 2024 · External reference
Glucose-Responsive Composite Microneedle Patch for Hypoglycemia-Triggered Delivery of Native Glucagon
10.1002/adma.201901051 · 2019 · External reference
Analysis of Glucose Responsive Glucagon Therapeutics Using Computational Models of the Glucoregulatory System
10.1002/adhm.202401410 · 2024 · External reference
Steady-State Differential Dose Response in Biological Systems
10.1016/j.bpj.2017.11.3780 · 2018 · External reference
Simultaneous Analysis of Families of Sigmoidal Curves: Application to Bioassay, Radioligand Assay, and Physiological Dose-Response Curves
10.1152/ajpendo.1978.235.2.e97 · 1978 · External reference
Defining and Reporting Hypoglycemia in Diabetes: A Report from the American Diabetes Association Workgroup on Hypoglycemia
10.2337/diacare.28.5.1245 · 2005 · External reference
Factors Affecting the Success of Glucagon Delivered during an Automated Closed-Loop System in Type 1 Diabetes
10.1016/j.jdiacomp.2014.09.001 · 2015 · External reference
Comparative Evaluation of Responsiveness of Insulin Counter-Regulatory Hormones and Insulin Resistance to Hypoglycemia in Newly Diagnosed Type 1 Diabetes Mellitus Man
10.2147/dmso.s554306 · 2025 · External reference
Glucose Counterregulation: Prevention and Correction of Hypoglycemia in Humans
10.1152/ajpendo.1993.264.2.e149 · 1993 · External reference
Mini-review: Glucagon Responses in Type 1 Diabetes – a Matter of Complexity
10.14814/phy2.15009 · 2021 · External reference
Role of Glucose, Insulin, and Glucagon in Glycogen Mobilization in Human Hepatocytes
10.2337/diab.40.2.263 · 1991 · External reference
Role of Glycogen Phosphorylase in Liver Glycogen Metabolism
10.1016/j.mam.2015.09.002 · 2015 · External reference
Insulin Regulation of Gluconeogenesis
10.1111/nyas.13435 · 2018 · External reference
The Use of Animal Models in Diabetes Research
10.1111/j.1476-5381.2012.01911.x · 2012 · External reference
Animal Models of Diabetes Mellitus
10.1111/j.1464-5491.2005.01499.x · 2005 · External reference
Animal Models for Type 1 and Type 2 Diabetes: Advantages and Limitations
10.3389/fendo.2024.1359685 · 2024 · External reference
Glucose-Fueled Peptide Assembly: Glucagon Delivery via Enzymatic Actuation
10.1021/jacs.1c04570 · 2021 · External reference
A Glucose-Responsive Glucagon-Micelle for the Prevention of Hypoglycemia
10.1021/acscentsci.4c00937 · 2024 · External reference
Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine–Phenylboronic Acid Pendant Modification
10.1002/smsc.202500555 · 2026 · External reference
Diabetes: Advances in Diagnosis and Treatment
10.1001/jama.2015.9536 · ExternalCitation · doi-reference
Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Provisional Report of a WHO Consultation
10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · ExternalCitation · doi-reference
A Pharmacokinetic Model of a Tissue Implantable Insulin Sensor
10.1002/adhm.201400264 · ExternalCitation · doi-reference
Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling
10.1002/adhm.201700601 · ExternalCitation · doi-reference
Rational Design and Efficacy of Glucose-Responsive Insulin Therapeutics and Insulin Delivery Systems by Computation Using Connected Human and Rodent Models
10.1002/adhm.202300587 · ExternalCitation · doi-reference
Analysis of Glucose Responsive Glucagon Therapeutics Using Computational Models of the Glucoregulatory System
10.1002/adhm.202401410 · ExternalCitation · doi-reference
Glucose-Responsive Composite Microneedle Patch for Hypoglycemia-Triggered Delivery of Native Glucagon
10.1002/adma.201901051 · ExternalCitation · doi-reference
Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation
10.1002/adma.201902004 · ExternalCitation · doi-reference
Shrinking Fabrication of a Glucose-Responsive Glucagon Microneedle Patch
10.1002/advs.202203274 · ExternalCitation · doi-reference
Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties
10.1002/cpt.1215 · ExternalCitation · doi-reference
A Model-Informed Drug Discovery and Development Strategy for the Novel Glucose-Responsive Insulin MK-2640 Enabled Rapid Decision Making
10.1002/cpt.1729 · ExternalCitation · doi-reference
Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine–Phenylboronic Acid Pendant Modification
10.1002/smsc.202500555 · ExternalCitation · doi-reference
Pharmacokinetics, Pharmacodynamics and Glucose Counterregulation Following Subcutaneous Injection of the Monomeric Insulin Analogue [Lys(B28),Pro(B29)] in IDDM
10.1007/bf00417697 · ExternalCitation · doi-reference
Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
10.1007/s00125-022-05744-z · ExternalCitation · doi-reference
Improved Postprandial Glycaemic Controls with Insulin Aspart in Type 2 Diabetic Patients Treated with Insulin
10.1007/s005920070034 · ExternalCitation · doi-reference
Development of Appropriate Equations for Physiologically Based Pharmacokinetic Modeling of Permeability-Limited and Flow-Limited Transport
10.1007/s10928-011-9200-x · ExternalCitation · doi-reference
Nonlinear Regression Modelling: A Primer with Applications and Caveats
10.1007/s11538-024-01274-4 · ExternalCitation · doi-reference
Steady-State Differential Dose Response in Biological Systems
10.1016/j.bpj.2017.11.3780 · ExternalCitation · doi-reference
Computer-Aided Drug Discovery and Development (CADDD): In Silico-Chemico-Biological Approach
10.1016/j.cbi.2006.12.006 · ExternalCitation · doi-reference
Metabolic Effects of Glucagon in Humans
10.1016/j.jcte.2018.12.005 · ExternalCitation · doi-reference
Factors Affecting the Success of Glucagon Delivered during an Automated Closed-Loop System in Type 1 Diabetes
10.1016/j.jdiacomp.2014.09.001 · ExternalCitation · doi-reference
Role of Glycogen Phosphorylase in Liver Glycogen Metabolism
10.1016/j.mam.2015.09.002 · ExternalCitation · doi-reference
Insulin Therapy and Exercise
10.1016/s0168-8227(11)70017-1 · ExternalCitation · doi-reference
ViVo: A Temporal Modeling Framework That Boosts Statistical Power and Minimizes Animal Usage
10.1021/acs.jmedchem.5c03326 · ExternalCitation · doi-reference
A Glucose-Responsive Glucagon-Micelle for the Prevention of Hypoglycemia
10.1021/acscentsci.4c00937 · ExternalCitation · doi-reference
Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design
10.1021/acsmaterialsau.4c00138 · ExternalCitation · doi-reference
In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins
10.1021/acsptsci.3c00095 · ExternalCitation · doi-reference
A Computational Glucoregulatory Model of Liver and Glucagon for the Evaluation of Therapeutics
10.1021/acsptsci.5c00177 · ExternalCitation · doi-reference
Glucose-Fueled Peptide Assembly: Glucagon Delivery via Enzymatic Actuation
10.1021/jacs.1c04570 · ExternalCitation · doi-reference
Pharmacokinetic and Glucodynamic Comparisons of Recombinant and Animal-Source Glucagon after IV, IM, and SC Injection in Healthy Volunteers
10.1021/js99007p · ExternalCitation · doi-reference
Pursuit of a Perfect Insulin
10.1038/nrd.2015.36 · ExternalCitation · doi-reference
Type 1 Diabetes Mellitus
10.1038/nrdp.2017.16 · ExternalCitation · doi-reference
Glucose-Sensitive Insulin with Attenuation of Hypoglycaemia
10.1038/s41586-024-08042-3 · ExternalCitation · doi-reference
In-Silico Experiments of Zebrafish Behaviour: Modeling Swimming in Three Dimensions
10.1038/srep39877 · ExternalCitation · doi-reference
Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes
10.1088/0967-3334/25/4/010 · ExternalCitation · doi-reference
Intensive Insulin Therapy (Basal-Bolus)
10.1097/mjt.0000000000001152 · ExternalCitation · doi-reference
Meal Simulation Model of the Glucose-Insulin System
10.1109/tbme.2007.893506 · ExternalCitation · doi-reference
Low Doses of Dasiglucagon Consistently Increase Plasma Glucose Levels from Hypoglycaemia and Euglycaemia in People with Type 1 Diabetes Mellitus
10.1111/dom.13562 · ExternalCitation · doi-reference
The Pathophysiology, Presentation and Classification of Type 1 Diabetes
10.1111/dom.16628 · ExternalCitation · doi-reference
Animal Models of Diabetes Mellitus
10.1111/j.1464-5491.2005.01499.x · ExternalCitation · doi-reference
The Use of Animal Models in Diabetes Research
10.1111/j.1476-5381.2012.01911.x · ExternalCitation · doi-reference
Insulin Regulation of Gluconeogenesis
10.1111/nyas.13435 · ExternalCitation · doi-reference
Simultaneous Analysis of Families of Sigmoidal Curves: Application to Bioassay, Radioligand Assay, and Physiological Dose-Response Curves
10.1152/ajpendo.1978.235.2.e97 · ExternalCitation · doi-reference
Glucose Counterregulation: Prevention and Correction of Hypoglycemia in Humans
10.1152/ajpendo.1993.264.2.e149 · ExternalCitation · doi-reference
The UVA/PADOVA Type 1 Diabetes Simulator
10.1177/1932296813514502 · ExternalCitation · doi-reference
The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
10.1177/1932296818757747 · ExternalCitation · doi-reference
Retained Diabetes Devices─A Literature Review
10.1177/19322968221105895 · ExternalCitation · doi-reference
Inpatient Use of Automated Insulin Delivery Systems
10.1177/19322968251412442 · ExternalCitation · doi-reference
Mini-review: Glucagon Responses in Type 1 Diabetes – a Matter of Complexity
10.14814/phy2.15009 · ExternalCitation · doi-reference
Glucose-Responsive Insulin and Glucagon Delivery (Dual-Hormone Artificial Pancreas) in Adults with Type 1 Diabetes: A Randomized Crossover Controlled Trial
10.1503/cmaj.121265 · ExternalCitation · doi-reference
Comparative Evaluation of Responsiveness of Insulin Counter-Regulatory Hormones and Insulin Resistance to Hypoglycemia in Newly Diagnosed Type 1 Diabetes Mellitus Man
10.2147/dmso.s554306 · ExternalCitation · doi-reference
Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin
10.2337/db19-0879 · ExternalCitation · doi-reference
Engineering a Pathway to Glucose-Responsive Therapeutics
10.2337/dbi23-0029 · ExternalCitation · doi-reference
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
10.2337/dc17-1402 · ExternalCitation · doi-reference
Economic Costs of Diabetes in the U.S. in 2022
10.2337/dci23-0085 · ExternalCitation · doi-reference
Role of Glucose, Insulin, and Glucagon in Glycogen Mobilization in Human Hepatocytes
10.2337/diab.40.2.263 · ExternalCitation · doi-reference
Diabetes and Heart Disease
10.2337/diacare.26.10.2947 · ExternalCitation · doi-reference
Defining and Reporting Hypoglycemia in Diabetes: A Report from the American Diabetes Association Workgroup on Hypoglycemia
10.2337/diacare.28.5.1245 · ExternalCitation · doi-reference
Epidemiology of Diabetes and Diabetes-Related Complications
10.2522/ptj.20080020 · ExternalCitation · doi-reference
Animal Models for Type 1 and Type 2 Diabetes: Advantages and Limitations
10.3389/fendo.2024.1359685 · ExternalCitation · doi-reference
Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?
10.3390/biom11091281 · ExternalCitation · doi-reference
Animal Models in Diabetic Research─History, Presence, and Future Perspectives
10.3390/biomedicines11102852 · ExternalCitation · doi-reference
Type 1 and Type 2 Diabetes Mellitus: Commonalities, Differences and the Importance of Exercise and Nutrition
10.3390/nu15194279 · ExternalCitation · doi-reference
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare
10.3390/pharmaceutics16030332 · ExternalCitation · doi-reference
Clinical Utility of Insulin and Insulin Analogs
10.4161/isl.24590 · ExternalCitation · doi-reference
